Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial

• Published in: ESMO open Vol. 6; no. 3; p. 100106
• Main Authors: de Guillebon, E., Jimenez, M., Mazzarella, L., Betsou, F., Stadler, P., Peták, I., Jeannot, E., Chanas, L., Servant, N., Marret, G., Duso, B.A., Legrand, F., Kornerup, K.N., Bernhart, S.H., Balogh, G., Dóczi, R., Filotás, P., Curigliano, G., Bièche, I., Guérin, J., Dirner, A., Neuzillet, C., Girard, N., Borcoman, E., Larbi Chérif, L., Tresca, P., Roufai, D.B., Dupain, C., Scholl, S., André, F., Fernandez, X., Filleron, T., Kamal, M., Le Tourneau, C.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-06-2021; Elsevier
• Subjects: Alphapapillomavirus; Carcinoma, Squamous Cell - drug therapy; epigenetics; HPV; Humans; Immunotherapy; Papillomaviridae; precision medicine clinical trial; Prospective Studies; Review; squamous cell carcinoma; precision medicine clinical trial; epigenetics; immunotherapy; squamous cell carcinoma; HPV
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2021.100106

Squamous cell carcinomas (SCCs) are among the most frequent solid tumors in humans. SCCs, related or not to the human papillomavirus, share common molecular features. Immunotherapies, and specifically immune checkpoint inhibitors, have been shown to improve overall survival in multiple cancer types, including SCCs. However, only a minority of patients experience a durable response with immunotherapy. Epigenetic modulation plays a major role in escaping tumor immunosurveillance and confers resistance to immune checkpoint inhibitors. Preclinical evidence suggests that modulating the epigenome might improve the efficacy of immunotherapy. We herein review the preclinical and the clinical rationale for combining immunotherapy with an epidrug, and detail the design of PEVOsq, a basket clinical trial combining pembrolizumab with vorinostat, a histone deacetylase inhibitor, in patients with SCCs of different locations. Sequential blood and tumor sampling will be collected in order to identify predictive and pharmacodynamics biomarkers of efficacy of the combination. We also present how clinical and biological data will be managed with the aim to enable the development of a prospective integrative platform to allow secure and controlled access to the project data as well as further exploitations.
•Squamous cell carcinomas (SCCs) of different locations share molecular features.•Immunotherapy improves overall survival in several cancers including SCCs.•Epigenetic modulation plays a major role in resistance to immunotherapy.•PEVOsq evaluates pembrolizumab/vorinostat combination in SCCs of several locations.•An integrative platform ensures secured optimal management of generated data.